My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  alliances  collaboration  partnering  alliance  alliance managers  partners  alliance manager  partner  partnerships  Ecosystem  The Rhythm of Business  governance  Jan Twombly  partnership  Strategic Alliance Magazine  Eli Lilly and Company  IoT  Vantage Partners  biopharma  Healthcare  NetApp  2015 ASAP Global Alliance Summit  ASAP BioPharma Conference  Cisco  strategy  Christine Carberry  Digital Transformation  IBM  innovation 

The Virtuous Cycle in Alliance Management—a Summit Spotlight Exclusive (Part 2)

Posted By Cynthia B. Hanson, Tuesday, March 5, 2019
Updated: Monday, March 4, 2019

“The alliance manager’s role is to understand the importance of timing,” advises Christine Carberry, CSAP, in Part One of ASAP Media’s interview with the seasoned alliance manager and former chief operating officer of Keryx Biopharmaceuticals (now a subsidiary of Akebia Therapeutics). Carberry, who also previously served as chair of the ASAP board of directors, will be providing a leadership spotlight plenary session, “Collaborate-Create: The Value of the Virtuous Cycle,” at the 2019 ASAP Global Alliance Summit, “Agile Partnering in Today’s Collaborative Ecosystem,” March 10-13 at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida. ASAP Media’s conversation with Carberry continues below.

Carberry’s role for six months of her year working for Keryx was as co-leader of integration planning with counterpart Akebia. Early on, she realized that her role wouldn’t continue with the new organization. She is philosophical about it. “You are working on trying to have everybody see the value of the merger—employees in the companies, investors, and shareholders. Yet people know you are not going to be part of it,” she explains of the challenge. “It’s about taking the time, if you can, to explore and not think that you have to jump right back into doing exactly what you were doing. Each experience leads to another.”

Alliance mangers are seekers of “the high road” trying to rise above conflict and egos, and keeping everyone focused on the common goal.  “You’re really a navigator,” she adds. “One of the criticisms that we’ve heard is alliance managers need to think of themselves much more broadly. And think of themselves as the people always looking for a portfolio of alliances and expanding value, not just be within the confines of agreements that you have today. That’s the challenge I want to give to the audience [at the Summit] in thinking about how we can have a greater impact by making better, stronger connections between ideas and resources, creating better conditions for collaboration. Your alliance portfolio is dynamic, and I think that alliance managers can create more value by really understanding that one alliance is one piece of a company portfolio and needs to align with company strategy.”

Before her one-year stint with Keryx, Carberry spent three and a half years with FORUM Pharmaceuticals (formerly EnVivo Pharmaceuticals) and 26 years with Biogen, where she stated out in an entry-level position during a time when genetic engineering was “scary science.” Biogen was a Fortune 500 international company that brought several drugs to patients “that changed their lives,” she adds. 

Despite being in transition between jobs, Carberry has “a very full plate.” In addition to her spotlight plenary session, as chairman emerita of ASAP, she will attend the Summit board and advisory meetings and will lead a roundtable about alliance management in a crisis situation. “It’s similar to what I’ve done in other transitional periods. It allows me to increase involvement in leadership roles,” she says.

Learn about Carberry’s talk and other leadership sessions and register for the 2019 ASAP Global Alliance Summit at http://asapsummit.org. See the ASAP Media team’s comprehensive before, during, and after coverage of the 2019 Summit in Strategic Alliance publications and on the ASAP blog.  

Tags:  Akebia Therapeutics  Alliance Excellence Award  alliance manager  Christine Carberry  conflict  digital  expanding value  Keryx Biopharmaceuticals  partnership  Patheon  strategic partner  technology  Thermo Fisher 

Share |
PermalinkComments (0)
 

The Virtuous Cycle in Alliance Management—a Summit Spotlight Exclusive (Part 1)

Posted By Cynthia B. Hanson, Tuesday, March 5, 2019
Updated: Monday, March 4, 2019

“There is a time and purpose for everything. So the alliance manager’s role is to understand the importance of timing.” Thus advises Christine Carberry, CSAP, a seasoned alliance manager and former chief operating officer of Keryx Biopharmaceuticals (now a subsidiary of Akebia Therapeutics). Carberry, who also previously served as chair of the ASAP board of directors, will be providing a leadership spotlight session “Collaborate-Create: The Value of the Virtuous Cycle” at the 2019 ASAP Global Alliance Summit, “Agile Partnering in Today’s Collaborative Ecosystem,” March 10-13 at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida.

A virtuous cycle connects right ideas with right resources in the right timing, she continues. “Timing is part of creating the right environment for collaboration and pulling those pieces together and then generating value,” Carberry explains. “That value often generates new ideas that just feed back into it. Growing new ideas may mean you need different kinds of resources. You may have an idea on how to improve a patient’s experience in a clinical trial. From that, you may come up with an idea that there’s a way to make that experience better using technology. Now you need different resources and skillsets to improve the patient experience in a digital way.”

Carberry’s talk is based on 30 years of management experience. Right now, she is between companies after Keryx Biopharmaceuticals and Akebia Therapeutics merged in December. The two companies are under consideration for a 2019 ASAP Alliance Excellence Award for their handling of a supply disruption where patients could not obtain a jointly manufactured drug. Access resumed after the companies teamed togetherfrom the C-level to the operational teamsto create a quick, viable solution.  

 

 “We had to navigate this partnership when Patheon merged with Fisher, and Keryx with Akebia,” Carberry explains. “Traditionally, biopharma companies treat CMOs as vendors, not as collaborators. … Applying all of the ASAP approaches and tools to the CMO I think creates a much stronger partnership, and it was demonstrated in this supply disruption situation. We needed high levels of trust with CEO engagement. It wasn’t business as usual. It was requiring people to go above and beyond,” she continues. “Agile is a good word for it. That willingness to be flexible and agile is less likely to happen if you are treating your CMO as a vendor rather than as strategic partner. “

 

See the ASAP Blog for Part Two of this interview with Christine Carberry, CSAP. Learn about Carberry’s plenary talk and other leadership sessions at the 2019 ASAP Global Alliance Summit, and register for the event, at http://asapsummit.org. See the ASAP Media team’s comprehensive before, during, and after coverage of the 2019 Summit in Strategic Alliance publications and on the ASAP blog.  

Tags:  Akebia Therapeutics  Alliance Excellence Award  alliance manager  Christine Carberry  digital  Keryx Biopharmaceuticals  partnership  Patheon  strategic partner  technology  Thermo Fisher 

Share |
PermalinkComments (0)
 

Change as a Constant: A Timely Session Planned for the ASAP BioPharma Conference

Posted By Geena B. Richards and Cynthia B. Hanson, Tuesday, October 23, 2018

Managing cycles of change is a session theme certain to unpack a profusion of thought-provoking ideas at the 2018 ASAP BioPharma Conference “Creating Valuable and Innovative Partnerships by Driving the Alliance Mindset,” September 24-26 at the Hyatt Regency Boston in Boston, Massachusetts USA. When change is afoot, alliance managers must learn how to quickly shift, dance, adapt, and evolve to keep pace in today’s meteoric biopharma partnering climate. How do alliance managers maintain an alliance mindset while negotiating fast-paced strategic changes, organizational shifts, and the introduction of new leadership? In a buzz of constant change, how do teams continue to listen to future needs? These are just a few of the challenges that will be addressed in the session “Leading Alliance Management amidst Shifting Corporate Strategy,” moderated by Andy Eibling, CSAP, senior partner at Forty86 Consulting Group. He will bring four panelists together to tackle this topic along with audience participation: Nick Dunscombe, vice president of business & commercial development at Astellas Pharma Europe; Mojgan Hossein-Nia, vice president, head of the R&D partnership office, Takeda; Steve Twait, CSAP, vice president alliance and integration management at AstraZeneca; Lucinda Warren, vice president business development, neuroscience, Johnson & Johnson Innovation/Janssen Business Development. Eibling recently provided a brief preview of some of the focal points the panelists plan to discuss.

What were some of the themes of this session?
Three of the four panelists have undergone significant changes in their careers. The fourth went through big organizational shifts not too long ago and has had multiple jobs within the organization. As the moderator, I will let them paint their own portrait and tell their own story and then go into targeted questions. We will discuss a lot of the problems associated with transitioning and how the panelists have solved them. We plan to stay within the alliance mindset and talk about how to ensure that the right mindset is in place as your alliance goes through strategic changes or as you are introduced into a new organization. Those changes could be an organizational shift from centralized to decentralized or a move to organize by therapeutic area to business unit. Changes to alliances, such as asset divestitures, will be covered. We will talk a little bit about tools and technology and how they are being used to learn and share expertise. As we talk about changes in strategies, we will get into metrics and how you can leverage them to ensure that you stay true to the alliances and their objectives. What metrics are companies incorporating to measure not just alliance health, but collaboration value? Another topic is how to design a Center of Excellence. This group has lots of expertise and different types of experiences.

What are some of the biggest challenges pharma alliance managers face today when dealing with corporate restructuring, both internally and externally?
That’s one of the themes we will address. As your organization shifts, by business unit or a move to a decentralized structure, what impact does that have? How does that change impact how your team performs? Constant change is the norm today as corporations strive to deliver much-needed innovative therapies to patients, increase revenues, and provide shareholder value. All the change we are talking about could be interpreted as ecosystem change for lasting solutions. The answers need to be flexible, not only relating to what you are going through now but predicting the next change as the pendulum swings. When the bowl of asset divestment wanes, what’s next? And do you have the right skills for the coming changes? What are the trends in non-traditional partnerships? Is the alliance language the same in the collaboration lifecycle?

What about adapting to changes in company culture? Will you be discussing these types of changes as well?
We are going to make sure to incorporate questions from the audience, and I wouldn’t be surprised if that comes up as a question. Nick Dunscombe, one of the panelists, just moved from a British to a Japanese company with a strong presence in the United States. He moved from alliance management at AstraZeneca to Astellas. Corporate culture might be something he could address. How do you apply what you know, what you learn, and how you shift? He will discuss best practices and the differences in the companies. Also, how do you adapt and how do you do it differently? What things worked in the past?

For more discussion of critical biopharma partnering topics and conference coverage, check out the Q2 and Q3 2018 issues of Strategic Alliance Magazine and the August 2018 issue of eSAM Plus.

Tags:  2018 ASAP BioPharma Conference  alliance manager  alliance mindset  Andy Eibling  Astellas  AstraZeneca  corporate culture  corporate restructuring  Johnson & Johnson Innovation  Lucinda Warren  Mojgan Hossein-Nia  Nick Dunscombe  non-traditional partnerships  Steve Twait  strategic challenges  Takeda 

Share |
PermalinkComments (0)
 

The Value of the Alliance Watchdog—Flagging and Wrestling with ‘Wicked Problems’

Posted By Geena B. Richards and Cynthia B. Hanson, Tuesday, September 18, 2018
Updated: Monday, September 17, 2018

“Wicked problems”—those stubborn, persnickety alliance challenges that defy easy answers—are sometimes difficult to pinpoint, discuss, and address in partnerships. Which is why Jeremy Ahouse, CSAP, vice president of alliances at Merus Pharmaceuticals, selected the topic to address head-on in his upcoming session “Grappling with Wicked Problems in Alliance Management” at the 2018 ASAP BioPharma Conference. The September 24-26 conference will be held for a second year at the Hyatt Regency Boston—conveniently located in the back bay near several esteemed academic and research institutions.

Never one to avoid a grueling topic, Ahouse developed his session after interviewing several senior alliance members about the hardest parts of alliances. Some of the seemingly intractable challenges were downright wicked, he concluded. Hence, his session on helping alliance managers learn how to confront and wrestle with the tough stuff.

“Wicked problems” can be particularly corrosive to meeting dynamics and challenging to contract clauses and/or shifting priorities. Ahouse pulls heavily from renowned public leadership guru Ron Heifetz for ideas on how to deal with such issue. There are three types of problems, he says. “In Type 1 problems, you agree on the problem definition and potential solutions. Project managers can often successfully address these,” he states. “In Type 2, we agree on our understanding of the problem but are still working on the solutions. In Type 3, we don’t even agree on what the problem is.”

An alliance manager must determine which type of problem they are facing to address it. Sometimes this process requires deep thinking and analysis because the problems are difficult to recognize and complex, which makes them so “wicked.” But there can be great value in wrestling with complexity, he purports. They may be tough to identify, but resolving problems is vital to partnerships. “Alliance managers are uniquely positioned to see problems that come out of interactions between companies and functions,” Ahouse points out. “This puts us in a position to notice early and alert our teams.”

This watchdog role is important to keep the collaboration running smoothly and most efficiently. There is no magic potion to addressing these issues, he quickly points out. “I don’t have simple answers to these problems.”

But discussing them makes them less “wicked,” he adds. And there are good, better, and best ways to communicate when a “wicked problem” surfaces.

Ahouse plans to focus on the challenges rather than success stories associated with these kinds of alliance problems. This way, the audience can have first-hand experience wrestling with real-life, hard problems that might get ignored in an alliance management situation.

The goal for the session is to create “an opportunity to start talking about [problems] and get ASAP members wrestling with them in a public forum,” he concludes. He plans “to stay away from simplistic answers” and encourage ASAP participants to think deeply about topics that need confrontation but many shy away from because of their complexity.

For more about Ahouse’s session, check out “'No Whitewash': Going Beyond 'Simplistic Answers' to the Toughest Alliance Management Challenges” in the July 2018 issue of eSAM Plus.

Tags:  alliance challenges  Alliance Management.#ASAP BioPharma  alliance manager  Jeremy Ahouse  Merus Pharmaceuticals  partnerships  Ron Heifetz 

Share |
PermalinkComments (0)
 

‘You Give Me a Buck, and We Give You Back Three’: Pharma Partnering Leaders Discuss Roles—and the Value of Alliance Management

Posted By Genevieve Fraser, Friday, April 13, 2018
Updated: Wednesday, April 11, 2018

The evolving roles of alliance executives—and capturing the value of the alliance function—were among the many topics that emerged as during the Tuesday, March 27 leadership panel discussion, “Driving Alliance Excellence into the Future,” moderated by Andy Eibling, CSAP, former Covance vice president of alliances, at the ASAP 2018 Global Alliance Summit, “Propelling Partnering for the On-Demand World: New Perspectives + Proven Practices for Collaborative Business,” March 26-28, 2018. Fort Lauderdale, Florida, USA.

 

Pharma executives joining Eibling for the discussion included Casey Capparelli, global product general manager in oncology at Amgen; Nancy Griffin, CA-AM, vice president and head of alliance management, global business development & licensing at Novartis; Mark Noguchi, vice president and global head, alliances and asset management, at Roche; and David S. Thompson, CA-AM, chief alliance officer, Eli Lilly and Company. (Editor’s Note: See the forthcoming April 2018 edition of eSAM Plus for more coverage of this fascinating leadership discussion.)

 

When Eibling threw out the topic of alliance management’s role in acquisitions, mergers, and divestments, and business development and licensing, he noted, “You need to differentiate between a stop and start in terms of divestments. Divestments can be ongoing. Someone in the group manages the ongoing process.”

 

Capparelli: In Amgen that holds true for small acquisitions, but large complex acquisitions need to be managed separately.

 

Thompson: You need to look to someone else to run a large acquisition.

 

Eibling: There’s lots happening in the pharma world today, but will it continue?

 

Thompson: There are more and more partnerships. The trend grows and grows. Today each alliance manager is involved with 20 to 30 alliances. How do you manage ever increasing volume? It’s hard to predict if something will come to fruition.

 

Eibling: Let’s look at the role of the alliance manager, and how it has shifted between project management and alliance management. Alliance management and project management need to be connected at the hip and carve out space through the partnership management team. There are three roles in a partnership management team. The question is who drives those team meetings? Who is accountable? Does the project manager manage the success of the alliance?

 

Thompson: Most M&A integration gets done in 100 days. The work looks the same except it’s compressed. It takes 100 days to swallow an alliance. It’s at a pace you need in an M&A.

 

Capparelli: Deal making is a transactional approach, but building trust generates respect.

 

Griffin: You build an operating model in the core so that you build consistent capabilities.

 

Noguchi: The Roche alliance group is modeled after Lilly. The skill set is there but compressed.

 

Eibling: There’s a shift between deal makers and an alliance manager with a partner. No one understands the dynamics as well as an alliance manager. With ever expanding projects, it’s the alliance manager who understands motivations and how to construct the alliance and M&A deal.

“Let’s look at value,” Eibling said, wrapping up the panel discussion. “How do you capture the value of alliance management? How do you define value?” he asked Thompson.

“Alliances are not efficient but effective,” Thompson asserted.

 

“Fear is a great motivator,” he continued. “I’ve seen too many alliances go out of existence. They focused on relationship management but didn’t expand beyond that to the legal and business risk. That contributed to their demise. They didn’t feel valued in the organization. So, in times of hardship, they’re an easy target to eliminate,” he explained.

 

“We saw it happening and so became open about our model. We measure continuation. We are adjudicated by leadership. It’s valuable to talk about your own contributions. You get the [internal] client you’re supporting to agree based on what they think—what they value or don’t value. Is this a risk reduction or efficiency game? You build to be efficient but it’s the face-to-face that often counts.  As for monetizing the value of alliance management, it’s simple. You give me a buck, and we give you back three.”

Tags:  acquisitions  alliance management  alliance manager  Amgen  Andy Eibling  Casey Capparelli  David S. Thompson  Eli Lilly and Company  leadership  M&A  M&A integration  Mark Noguchi  Nancy Griffin  Novartis  partner  partnerships  Pharma executives  project manager  Roche 

Share |
PermalinkComments (0)
 
Page 1 of 5
1  |  2  |  3  |  4  |  5
For more information email us at info@strategic-alliances.org or call +1-781-562-1630